×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CGON – cg oncology, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CGON
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
08:13 am
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting [Yahoo! Finance]
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting [Yahoo! Finance]
11/20
08:00 am
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
11/14
07:09 am
cgon
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
08:33 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
High
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
11/12
08:00 am
cgon
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/11
08:00 am
cgon
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
Low
Report
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
10/24
07:16 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $60.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $60.00 price target on the stock.
10/8
11:48 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $65.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $65.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
02:31 pm
cgon
Form SC 13G/A CG Oncology, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A CG Oncology, Inc. Filed by: VANGUARD GROUP INC
11/12
09:41 am
cgon
Form 10-Q CG Oncology, Inc. For: Sep 30
Medium
Report
Form 10-Q CG Oncology, Inc. For: Sep 30
11/12
09:26 am
cgon
Form 8-K CG Oncology, Inc. For: Nov 12
High
Report
Form 8-K CG Oncology, Inc. For: Nov 12
11/8
02:19 pm
cgon
Form SC 13G CG Oncology, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G CG Oncology, Inc. Filed by: BlackRock, Inc.
11/4
10:23 am
cgon
Form SC 13G/A CG Oncology, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A CG Oncology, Inc. Filed by: VANGUARD GROUP INC
10/22
06:08 pm
cgon
Form SC 13G CG Oncology, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G CG Oncology, Inc. Filed by: BlackRock, Inc.
10/8
09:30 am
cgon
Form 4 CG Oncology, Inc. For: Oct 04 Filed by: Roche Corleen M.
Low
Report
Form 4 CG Oncology, Inc. For: Oct 04 Filed by: Roche Corleen M.
10/7
05:18 pm
cgon
Form 4 CG Oncology, Inc. For: Oct 04 Filed by: POST LEONARD E
Low
Report
Form 4 CG Oncology, Inc. For: Oct 04 Filed by: POST LEONARD E
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: